Lineage Cell Therapeutics


BioTime, Inc. is a clinical-stage biotechnology company headquartered in Alameda, California. BioTime stock is traded on the New York Stock Exchange American Exchange under ticker symbol BTX. BioTime focuses primarily on aesthetics, ophthalmology
and cell and drug delivery.
The company is in clinical trials for dry age-related macular degeneration and facial lipoatrophy in HIV patients

History

BioTime was founded in 1990 in Berkeley, California with an initial focus on developing processes to cool living bodies and related projects.
In 2007, the company appointed Michael D. West, Ph.D, as chief executive officer. West had been CSO and CEO of Advanced Cell Technology, which later changed its name to Ocata Therapeutics and was sold to Astellas Pharma in 2016. Prior to that had founded Geron.
In 2009, BioTime secured $4.72 million in grant funding from the California Institute for Regenerative Medicine.

Subsidiaries

BioTime's subsidiaries include:
BioTime’s Board of Directors includes: